Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons.
Amphetamine
/ pharmacology
Animals
Cannabinoids
/ pharmacology
Central Nervous System Stimulants
/ pharmacology
Cocaine
/ pharmacology
Conditioning, Operant
/ drug effects
Dopamine Plasma Membrane Transport Proteins
/ genetics
Dopaminergic Neurons
/ drug effects
Eukaryotic Initiation Factor-3
/ genetics
Gene Expression Regulation
/ drug effects
Hyperkinesis
/ chemically induced
Locomotion
/ drug effects
Mice
Mice, Inbred C57BL
Mice, Transgenic
Nicotine
/ pharmacology
RNA, Messenger
/ metabolism
Receptor, Cannabinoid, CB2
/ deficiency
Statistics, Nonparametric
Time Factors
Tyrosine 3-Monooxygenase
/ metabolism
Amphetamine
CB2 cannabinoid receptors
Cocaine
Conditioned place preference
Mice
Nicotine
Journal
Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872
Informations de publication
Date de publication:
15 03 2019
15 03 2019
Historique:
received:
19
08
2018
revised:
15
11
2018
accepted:
29
11
2018
pubmed:
7
12
2018
medline:
3
5
2019
entrez:
4
12
2018
Statut:
ppublish
Résumé
Activation of the endocannabinoid system modulate dopaminergic pathways that are involved in the effects of psychostimulants including amphetamine, cocaine, nicotine and other drugs of abuse. Genetic deletion or pharmacological activation of CB2 cannabinoid receptor is involved in the modulation of the effects of psychostimulants and their rewarding properties. Here we report on the behavioral effects of psychostimulants in DAT-Cnr2 conditional knockout (cKO) mice with selective deletion of type 2 cannabinoid receptors in dopamine neurons. There was enhanced psychostimulant induced hyperactivity in DAT-Cnr2 cKO mice, but the psychostimulant-induced sensitization was absent in DAT-Cnr2 cKO compared to the WT mice. Intriguingly, lower doses of amphetamine reduced locomotor activity of the DAT-Cnr2 cKO mice. While cocaine, amphetamine and methamphetamine produced robust conditioned place preference (CPP) in both DAT-Cnr2 cKO and WT mice, nicotine at the dose used induced CPP only in the WT but not in the DAT-Cn2 cKO mice. However, pre-treatment with the CB2R selective agonist JWH133, blocked cocaine and nicotine induced CPP in the WT mice. The deletion of CB2Rs in dopamine neurons modified the levels of tyrosine hydroxylase, and reduced the expression of dopamine transporter gene expression in DAT-Cnr2 cKO midbrain region. Taken together, our data suggest that CB2Rs play a role in the modulation of dopamine-related effects of psychostimulants and could be exploited as therapeutic target in psychostimulant addiction and other psychiatric disorders associated with dopamine dysregulation.
Identifiants
pubmed: 30508607
pii: S0166-4328(18)31198-7
doi: 10.1016/j.bbr.2018.11.043
pmc: PMC6327973
mid: NIHMS1517111
pii:
doi:
Substances chimiques
Cannabinoids
0
Central Nervous System Stimulants
0
Dopamine Plasma Membrane Transport Proteins
0
Eukaryotic Initiation Factor-3
0
RNA, Messenger
0
Receptor, Cannabinoid, CB2
0
Nicotine
6M3C89ZY6R
Amphetamine
CK833KGX7E
Tyrosine 3-Monooxygenase
EC 1.14.16.2
Cocaine
I5Y540LHVR
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC
TDG8048RDA
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
286-297Subventions
Organisme : NIDA NIH HHS
ID : R01 DA021409
Pays : United States
Organisme : NIDA NIH HHS
ID : R15 DA032890
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA031573
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 DA999999
Pays : United States
Informations de copyright
Published by Elsevier B.V.
Références
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5780-5
pubmed: 10318961
Behav Neurosci. 2015 Feb;129(1):37-41
pubmed: 25546366
Neuro Endocrinol Lett. 2006 Feb-Apr;27(1-2):63-9
pubmed: 16648795
Br J Pharmacol. 2004 Sep;143(2):227-34
pubmed: 15313883
Neuropharmacology. 2008 Jan;54(1):95-107
pubmed: 17655884
Psychopharmacology (Berl). 1999 May;144(2):95-110
pubmed: 10394990
Neuropsychiatr Dis Treat. 2007 Dec;3(6):711-21
pubmed: 19300605
Pharmacol Biochem Behav. 2005 Jun;81(2):263-84
pubmed: 15936806
Int J Neuropsychopharmacol. 2017 Mar 1;20(3):269-278
pubmed: 27994006
Psychopharmacology (Berl). 2009 May;204(1):1-11
pubmed: 19099297
Psychopharmacology (Berl). 2013 Oct;229(4):591-601
pubmed: 23652588
Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
pubmed: 8401595
Trends Neurosci. 2006 Apr;29(4):225-32
pubmed: 16483675
Neuroscience. 1998 Mar;83(2):393-411
pubmed: 9460749
PLoS One. 2014 May 20;9(5):e98079
pubmed: 24844285
Nature. 2007 Jan 11;445(7124):168-76
pubmed: 17151600
J Neurosci. 2010 Jul 21;30(29):9877-89
pubmed: 20660270
Psychopharmacology (Berl). 2016 Mar;233(6):995-1003
pubmed: 26676982
Behav Pharmacol. 2008 Sep;19(5-6):575-81
pubmed: 18690112
Behav Brain Res. 2002 Dec 2;137(1-2):75-114
pubmed: 12445717
Pharmacol Biochem Behav. 2008 May;89(3):384-91
pubmed: 18294680
J Addict Dis. 2001;20(3):43-54
pubmed: 11681592
Nat Rev Neurosci. 2004 Jun;5(6):483-94
pubmed: 15152198
Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):E5007-15
pubmed: 25368177
Neuropsychopharmacology. 2013 Nov;38(12):2515-24
pubmed: 23817165
Annu Rev Neurosci. 2006;29:565-98
pubmed: 16776597
Science. 2005 Oct 14;310(5746):329-32
pubmed: 16224028
Adv Biochem Psychopharmacol. 1975;13:247-62
pubmed: 1171583
Eur J Pharmacol. 1999 Jul 14;377(1):117-25
pubmed: 10448934
Neurosci Biobehav Rev. 2006;30(2):215-38
pubmed: 16099045
J Neurosci. 2007 Jan 24;27(4):791-5
pubmed: 17251418
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
J Neurosci. 2007 Jun 27;27(26):6937-47
pubmed: 17596442
Br J Pharmacol. 2008 May;154(2):369-83
pubmed: 18414385
J Neurochem. 1996 Aug;67(2):443-62
pubmed: 8764568
J Biol Chem. 2012 Jun 15;287(25):20851-65
pubmed: 22532560
Nat Neurosci. 2011 Jul 24;14(9):1160-6
pubmed: 21785434
J Neuroinflammation. 2018 May 24;15(1):158
pubmed: 29793509
Science. 1991 Oct 25;254(5031):578-9
pubmed: 1948035
Sci Rep. 2017 Dec 12;7(1):17410
pubmed: 29234141
Brain Res Rev. 2007 Nov;56(1):27-78
pubmed: 17574681
J Neurosci. 2016 May 4;36(18):5160-9
pubmed: 27147666
PLoS One. 2008 Feb 20;3(2):e1640
pubmed: 18286196
Nature. 1998 Jan 8;391(6663):173-7
pubmed: 9428762
Synapse. 2008 Dec;62(12):944-9
pubmed: 18798269
Neuron. 2016 May 18;90(4):795-809
pubmed: 27133464
Neuropsychopharmacology. 2012 Jun;37(7):1749-63
pubmed: 22414816
Neuroscience. 1999;92(4):1177-91
pubmed: 10426477
Ann N Y Acad Sci. 2006 Aug;1074:514-36
pubmed: 17105950
Trends Neurosci. 1998 Dec;21(12):521-8
pubmed: 9881850
J Pharmacol Exp Ther. 2008 Aug;326(2):483-92
pubmed: 18451315
Brain Res. 2006 Feb 3;1071(1):10-23
pubmed: 16472786
Annu Rev Pharmacol Toxicol. 1996;36:597-613
pubmed: 8725403
J Leukoc Biol. 2005 Dec;78(6):1192-7
pubmed: 16204639
Neuropsychopharmacology. 2005 Sep;30(9):1670-80
pubmed: 15742004
J Neurosci. 2002 Aug 15;22(16):6900-7
pubmed: 12177188
Nat Rev Neurosci. 2015 May;16(5):305-12
pubmed: 25873042
Eur J Pharmacol. 2000 Oct 6;406(1):1-13
pubmed: 11011026